Main Menu

Flexion Therapeutics, Inc.

(NASDAQ GM: FLXN)

Rigrodsky Law, P.A. is investigating Flexion Therapeutics, Inc. (“Flexion”) regarding possible breaches of fiduciary duties and other violations of law related to Flexion’s agreement to be acquired by Pacira BioSciences, Inc. Under the terms of the agreement, Flexion’s shareholders will receive $8.50 in cash and one non-tradeable contingent value right worth up to $8.00 per share

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 10/22/2021


* Indicates a required field.

Back to Page